Memphasys

Memphasys Forward P/E

Forward P/E-forhold for Memphasys (MEM.AX) pr. 22. okt. 2026 er -4,86. I foregående år var Forward P/E-forhold -4,03 — en ændring på 20,43 % (lavere).

Forward P/E

-4,86

YoY

20,43%

Senest opdateret:

Forward P/E-forhold for Memphasys er 2026 -4,86 . Forward P/E-forhold for Memphasys var 2025 -4,03 . Det falder dermed med 20,43% lavere sammenlignet med året før.

Memphasys Forward P/E historik

  • 3 år

  • 10 år

  • 25 år

  • Maks

Forward P/E
Dato
Forward P/E
1. jan. 2019
-19,08 AUD
1. jan. 2020
-17,58 AUD
1. jan. 2021
-13,41 AUD
1. jan. 2022
-9,57 AUD
1. jan. 2023
-5,86 AUD
1. jan. 2024
-4,49 AUD
1. jan. 2025
-4,03 AUD
1. jan. 2026
-4,86 AUD
Memphasys Forward P/E historik
ÅRForward P/EYoY
-4,86+20,43%
-4,03-10,12%
-4,49-23,40%
-5,86-38,81%
-9,57-28,60%
-13,41-23,72%
-17,58-7,88%
-19,08-61,60%
-49,68+398,53%
-9,97+8,74%
-9,16+8,52%
-8,45+62,80%
-5,19—

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

Memphasys Aktieanalyse

Hvad laver Memphasys? Memphasys Ltd. develops medical devices, diagnostics, and media for assisted reproduction technology (ART) in humans and animals. The company's product pipeline includes Felix, a patented automated device for separating high-quality sperm from semen in human IVF procedures, ROSA, an in vitro diagnostic for assessing oxidative stress in semen and blood samples, and AI-Port, a system for storing and transporting animal semen without freezing for up to four days. Felix targets the global IVF market, ROSA serves clinics and research facilities analyzing reproductive health, and AI-Port is designed for livestock artificial insemination providers. The company monetizes through direct sales of these proprietary products to healthcare providers, fertility clinics, and agricultural biotechnology firms. Felix, with its patented technology for DNA-safe sperm separation, addresses a significant market need in human fertility treatments. ROSA provides diagnostic capabilities for clinics evaluating oxidative stress in reproductive samples, while AI-Port offers a competitive advantage in livestock breeding by eliminating the need for frozen semen transport. These products are sold directly to specialized buyers within their respective sectors without intermediaries. The company generates revenue primarily from the sale of its three core products: Felix for human IVF, ROSA for diagnostic assessments, and AI-Port for animal semen storage and transport. These products target distinct segments—human fertility clinics, reproductive health research institutions, and livestock artificial insemination businesses—each with clear purchasing patterns and demand drivers. Memphasys focuses on selling directly to these end-users rather than through third-party distributors. Memphasys er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Memphasys aktie

Forward P/E-forhold for Memphasys er -4,86 i 2026.

Forward P/E-forhold for Memphasys ændrede sig fra -4,03 til -4,86, hvilket repræsenterer en ændring på 20,43 %. Værdien er lavere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af Forward P/E-forhold Memphasys siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

Forward P/E bruger estimeret fremtidig indtjening til at værdiansætte en aktie. Et lavere forward P/E i forhold til bagudrettet P/E tyder på, at analytikere forventer vækst i indtjeningen.

For at evaluere Forward P/E-forholds er det afgørende at sammenligne det med andre virksomheder i samme branche og sektor. På Eulerpool kan du finde branchsammenligninger for Forward P/E-forhold.

En 'god' varierer efter branche og virksomhedens udviklingsstadium. På Eulerpool kan du sammenligne Forward P/E-forholds Memphasys med konkurrenter og branchegjennemsnittet for at afgøre, om den er attraktiv.

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

Værdiansættelse — Memphasys

Alle nøgletal — Memphasys